The Institute of Bioorganic Chemistry offers consumers diagnostic oligonucleotide kits for the determination of genetic markers of pharmacoresistance in psychotropic drugs "OLIGO-GENFARM" under a manufacturing agreement, as well as services for the determination of genetic markers under an outsourcing agreement and is looking for partners interested in a distribution services agreement.

Genetic criteria of pharmacoresistance to psychotropic drugs have been developed and introduced into medical practice to determine the treatment tactics for patients with mental disorders and substance dependence syndrome.

A method for determining pharmacoresistance to psychotropic drugs has been developed. The use of genetic criteria of pharmacoresistance to psychotropic drugs to determine the treatment tactics for patients with mental disorders and substance dependence syndrome will allow predicting the clinical course of the disease and the likelihood of complications, taking into account the features of drug metabolism and determining individual sensitivity to drugs. Based on the information obtained, a personalized selection of the necessary treatment can be carried out, which will reduce the number and duration of hospitalization, premature mortality of patients with psychiatric and drug addiction profiles. The developed set of diagnostic oligonucleotides will significantly reduce the time of molecular genetic analysis when determining numerous genetic markers, while being characterized by high reproducibility, specificity, and accuracy of the obtained results of genetic analysis.

Information is posted in  Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), p. 177-178. (in Russian)

Our production allows us to quickly supply the required number of kits and provide ongoing technical support to consumers.

The use and application of the kits do not pose any environmental risks.

The Oligo-GenFarm kit is designed to detect 21 genetic markers of pharmacoresistance to psychotropic drugs in human genomic DNA: CYP2C9*2 (430C>T, rs1799853), CYP2C9*3 (1075A>C, rs1057910), CYP2C19*2 (681G>A, rs4244285), CYP2C19*17 (–806C>T, rs12248560), CYP2D6*4 (1846G>A, rs3892097), CYP2D6*41 (2988G>A, rs28371725), CYP2В6*6 (516G>T, rs3745274), CYP1А2*F (–163C>A, rs762551), MDR (C3435T, rs1045642), UGT1A1*28 (A(TA)6TAA to A(TA)7TAA, rs8175347), НТR1А(С-1019G, rs6295), HTR2С (C>G, intronic variant, rs1414334), DRD1 (C>T, rs4532), DRD2 (C957T, rs6277), ANKK1 (ankyrin kinase 1, closely related to DRD2 (c.2137 G>A, E713K (E [GAG] > K [AAG]), rs1800497), SLC6A4 (5-HTTLPR, rs25532), СОМТ (Val158Met (G>A), rs4680; C>T, rs13306278); CACNG2 (C>T intronic variant, rs2284018), HLA-A 31:01:02 (rs1061235), MAOA-uVNTR (2,3,4,5 tamdem repeats), to determine the treatment tactics for patients with mental disorders, substance abuse syndrome.

The required amount of DNA for analysis is 2-20 ng per reaction.

The average cost of determining 1 genetic marker using commercial kits is 8-10 US dollars. The estimated cost of one analysis using the developed set of diagnostic oligonucleotides is no more than 5 US dollars. The cost reduction is due to the use of our developments and reagents produced by the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus.

The developed technologies for manufacturing reagent kits are protected as a commercial secret.

A method for individual selection of drugs and their dosage regimen for mental and behavioral disorders based on the results of pharmacogenetic testing: patent. 23102 Rep. Belarus / T. V. Dokukina, A. A. Gilep, T. S. Golubeva, M. V. Makhrov, I. V. Gaidukevich, S. A. Marchuk, E. A. Sheremet, A. S. Pinchuk, A. V. Romensky, K. S. Zharankov, V. V. Dokukina; date published: 10.06.2020.

Currently, the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus is one of the well-known scientific centers for the study of the most important biopolymers (proteins, enzymes, nucleic acids) and low-molecular bioregulators (steroid hormones of humans, insects and plants, peptides, phospholipids, prostaglandins and their synthetic analogues).

Main areas of activity:
- fundamental and applied research in the field of chemistry, structure and function of biopolymers and low-molecular bioregulators, including proteins, nucleic acids and their components, phospholipids, steroids, prostaglandins, brassinosteroids, ecdysteroids;
- development and pilot production of immunochemical and molecular biological reagent kits for medical and veterinary diagnostics;
- development and production of pharmaceutical substances, hormonal drugs and biospecific hemosorbents;
- development of technologies for the production and use of growth stimulants and plant protection products;
- experimental and clinical pharmacology, pharmacy and drug technology, toxicology, human and animal biochemistry, biomedical and pharmaceutical chemistry;
- preclinical, bioequivalent and pharmaceutical testing.

Main research areas:
- organic and bioorganic chemistry of low-molecular bioregulators (steroids, peptides, prostaglandins, lipids, nucleosides and nucleotides) and the most important biopolymers, including proteins and nucleic acids, establishing patterns of their functioning in living systems;
- development of new chemical, chemical-enzymatic and genetic engineering methods for obtaining biopolymers and low-molecular bioregulators and their analogues in order to create drugs for medicine and agriculture on their basis;
- study of the structure, physicochemical properties and biological activity of natural biomolecules and their analogues, establishing the relationship between their structure and biological activity, development of scientific principles for targeted search for substances with predictable biological activity;
- study of the structure, function and mechanism of action of enzyme systems of biosynthesis and metabolism of the most important natural bioregulators and xenobiotics;
- development of technologies for the production of reagents for medical diagnostics, drugs and chemical plant protection products.

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For the pilot production of the developed products (hemosorbents, recombinant enzyme preparations, immunochemical reagents, oxyphytosterols, etc.), the institute has created 5 pilot production sites.

The results of fundamental and applied research on methods and means of plant protection against diseases, insects, weeds and other adverse environmental factors that are safe for humans and the biosphere as a whole served as the foundation for developing methods for obtaining new plant growth stimulants, pheromone compositions (pheromones of the codling moth LP-U and the miller moth), active ingredients of pesticides (analogues of the herbicide Grasp and the insecticide Confidor), preparative forms of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of valid patents, laboratory technological and pilot-industrial regulations, technical specifications, and trademarks. There are license agreements in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents and pesticides to manufacturers.

The Institute of Bioorganic Chemistry successfully develops international relations in the main areas of its research. Currently, the institute conducts joint research with scientific institutes in the CIS countries, Germany, the USA, Canada, Sweden, Finland, Denmark, Holland, Vietnam and other countries.

Consumers interested in purchasing diagnostic oligonucleotide kits for determining genetic markers of pharmacoresistance in psychotropic drugs "OLIGO-GENFARM" under a manufacturing agreement, as well as services for determining genetic markers under an outsourcing agreement.

Partners interested in purchasing diagnostic oligonucleotide kits for determining genetic markers of pharmacoresistance in psychotropic drugs "OLIGO-GENFARM" under a distribution services agreement.